Gilead Connecticut, Inc.

Genentech, Inc.

Telik, Inc.

Cgi Pharmaceuticals, Inc.

Icos Corporation

Genetech, Inc.

Deltagen Research Labs, LLC

Pavel E Zhichkin

Scott A Mitchell

Peter A Blomgren

Kevin S Currie

Jeffrey E Kropf

Jianjun Xu

Seung H Lee

Zhongdong Zhao

Aaron C Schmitt

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Antonio J M Barbosa

Honglu Zhang

Ravi Krishnamoorthy

Steven R Schow

David R Brittelli

R Jason Herr

Matthew Ernst Voss

Harold Meckler

Douglas Gregory Stafford

William Allen Boulanger

Mihaela Diana Danca

Antonio J Barbosa

Dennis L Edie

Pedro E Hernandez Abad

Ronan Y Guevel

Steven James Collier

Kerry W Fowler

Robert T Lum

Jaimie Karyn Rueter

Danwen Huang

Michael R Kozlowski

Qin Jiang

Graham Beaton

Fanying Meng

Russell Dahl

Wilna J Moree

David L McElligott

David John Fairfax

Erik Christenson

Phyllis S Goldman

William Martin Rennells

Helge A Reisch

Stephen A Eastham

Ren Hua Song

Lisa H Bourdon

Jaimie E Bertino

Dan Herendeen

Anthony J Demaggio

Robert E Polomski

Hans J Kjaersgaard

Douglas G Stafford

Steven J Collier

William M Rennells

Pedro E Hernández Abad

Jason R Herr

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyridone and aza-pyridone compounds and methods of use

Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described. 

Pyridazinones, method of making, and method of use thereof

The invention relates to compounds of the following Formula I wherein R, R, Z, W, and D are defined herein, that inhibit Btk and therefore are useful in the treatment of diseases responsive to inhibition of Btk activity such as cancer. The invention also relates to pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, as well as methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described, and methods for determining the presence of Btk in a sample.

Certain substituted amides, method of making, and method of use thereof

A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.

Process for and intermediates in the preparation of canfosfamide and its salts

Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

Certain substituted ureas, as modulators of kinase activity

Certain substituted pyrazinones

The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula:or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q, Qand Y are those defined herein.

PARP inhibitors

Bis-(N,N&prime;-bis-(2-haloethyl)amino)phosphoramidates, pharmaceutical compositions containing them, methods of treatment using them, and processes for their preparation. The compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of cancer.

Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents

Growing community of inventors

Delmar, NY, United States of America

Pavel E Zhichkin